Product Family: Pincer Lung Cell Model
Disease Area: Cancer
Tissue Type: Lung
Clinical Diagnosis: Adenocarcinoma, Invasive

Disease Area:	Cancer
Tissue Type:	Lung
Clinical Diagnosis:	Adenocarcinoma, Invasive
Age:	65-70
Sex:	Female
Ethnicity:	Caucasian
TNM Stage:	T2aN0MX
Grade:	IB
Treatment History:	No prior treatment
Co-indications:	Sensory loss in hands, Joint crepitus, Osteoarthritis, Seizure disorder, Lung nodule, Malignant neoplasm of the lung, Chronic obstructive pulmonary disease, Irritable bowel syndrome, Hypertension, Arthritis, Hypothyroidism, Depression, Hyperlipidemia
Medications:	Metoprolol, Albuterol, Dicyclomine, Cyclobenzaprine, Fluticasone and salmeterol, Memantine HCl, Donepezil, Diphenhydramine, Tiotropium bromide monohydrate, Ropinirole
Country of Collection:	United States
Year of Origin:	2016

MORPHOLOGY (2D)

 

MUTATIONS

 

Gene	Alteration	Frequency (%)	Exon	Result
PBRM1	A1073S	75	21	Mutated, Variant of Unknown Significance
BMPR1A	R443C	70	11	Mutated, Variant of Unknown Significance
TP53	N239S	47	7	Mutated, Presumed Pathogenic
RAF1	S259F	46	7	Mutated, Pathogenic
SMO	R709fs	12	12	Mutated, Variant of Unknown Significance
KDR (VEGFR2)	E730K	8	15	Mutated, Variant of Unknown Significance

 

PINCER DRUG RESPONSE

The Pincer Cell Model demonstrates sensitivity to Cisplatin and Etoposide, while showing resistance to Larotrectinib.

PINCER GROWTH CHARACTERISTICS

The growth curve of Pincer demonstrates consistent and rapid growth. Pincer cells grow continuously for 15+ passages.

• Product Sheet
• Certificate of Analysis

CELL LINE PROTOCOL

See Passaging Protocol: Lung Cohort for detailed Protocol

STORAGE AND SAFETY

Storage and Stability: Store frozen in liquid nitrogen.

Quality Control: All lots are tested for consistent growth capabilities. See Certificate of Analysis for further details.